Identifying Genetic Mutations in Lobular Breast Cancer Patients
LobularCard Trial: Searching for Novel Germline Mutations in Lobular Breast Cancer Patients
This study is trying to find out how common certain genetic mutations are in patients with lobular breast cancer to see if these findings can help guide their future care.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 800 (estimated) |
| Ages | 18 Years to 99 Years |
| Sex | Female |
| Sponsor | European Institute of Oncology Academic / other |
| Locations | 1 site (Milan) |
| Trial ID | NCT05410951 on ClinicalTrials.gov |
What this trial studies
This observational study focuses on patients diagnosed with invasive lobular breast cancer or lobular in situ neoplasia. It aims to identify the frequency of germline mutations using a comprehensive panel of 113 genes through Next Generation Sequencing technology. If novel mutations are discovered, personalized follow-up care or prophylactic mastectomy will be offered based on the mutation's penetrance. Patients will undergo regular screenings and follow-ups for five years to monitor their health.
Who should consider this trial
Good fit: Ideal candidates include individuals diagnosed with invasive lobular breast cancer or lobular in situ neoplasia who have available blood samples in a biobank.
Not a fit: Patients with previous cancers (other than skin basal cell carcinoma) or those diagnosed with ductal or mixed breast cancer may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to better personalized treatment options and preventive measures for patients with lobular breast cancer.
How similar studies have performed: While this approach is novel in its specific focus on lobular breast cancer, similar studies have successfully identified genetic mutations in other breast cancer types.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion criteria: 1. All LBC observed retrospectively at the European Institute of Oncology, with a proved diagnosis of LBC (biopsy or operated) 2. Patients with blood available in biobank Exclusion criteria * Patients with a previous cancer (except skin basal cell carcinoma) * Patients with ductal or mixed BC
Where this trial is running
Milan
- European Institute of Oncology — Milan, Italy (Recruiting)
Study contacts
- Principal investigator: Giovanni Corso, PhD, MD — European Institute of Oncology
- Study coordinator: Giovanni Corso, PhD
- Email: giovanni.corso@ieo.it
- Phone: +390294375161
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.